Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 6, 2005, Pages 1411-1417

  Aiello, Erin J ^a   Tworoger, Shelley S ^d   Yasui, Yutaka ^a   Stanczyk, Frank Z ^e   Potter, John ^a,b   Ulrich, Cornelia M ^a,b   Irwin, Melinda ^f   McTiernan, Anne ^a,b,c,g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CHOLESTEROL; ESTRADIOL; ESTRONE; LOW DENSITY LIPOPROTEIN; PRASTERONE; SEX HORMONE; SOMATOMEDIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPUTER ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; IMAGE DISPLAY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; BREAST; FEMALE; GONADAL STEROID HORMONES; HUMANS; LIPIDS; MAMMOGRAPHY; MIDDLE AGED; OBESITY; POSTMENOPAUSE; SOMATOMEDINS;

EID: 20444394741     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0920     Document Type: Article

References (50)

1. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003;5:R129-35.
2. Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000;92:1081-7.
3. Kato I, Beinart C, Bleich A, et al. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). Cancer Causes Control 1995;6:431-8.
4. Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 1976;37:2486-92.
5. Goodwin PJ, Boyd NF. Mammographic parenchymal pattern and breast cancer risk: a critical appraisal of the evidence. Am J Epidemiol 1988;127:1097-108.
6. Salminen TM, Saarenmaa IE, Heikkila MM, Hakama M. Risk of breast cancer and changes in mammographic parenchymal patterns over time. Acta Oncol 1998;37:547-51.
7. El-Bastawissi AY, White E, Mandelson MT, Taplin SH. Reproductive and hormonal factors associated with mammographic breast density by age (United States). Cancer Causes Control 2000;11:955-63.
8. Laya MB, Gallagher JC, Schreiman JS, et al. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7.
9. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal estrogen/progestin interventions (PEPI) investigators. Ann Intern Med 1999; 130:262-9.
10. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
11. McNicholas MM, Heneghan JP, Milner MH, et al. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR Am J Roentgenol 1994;163:311-5.
12. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.
13. Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003 Jan 1;95:30-7.
14. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002 Feb 13;287:734-41.
15. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002 Jul 17;288:321-33.
16. Olsson H, Bladstrom A, Ingvar C, Moller TR. A populanon-basedcohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 2001;85:674-7.
17. Meyer F, Brisson J, Morrison AS, Brown JB. Endogenous sex hormones, prolactin, and mammographic features of breast tissue in premenopausal women. J Natl Cancer Inst 1986;77:617-20.
18. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002 Oct 7;87:876-82.
19. Boyd NF, McGuire V, Fishell E, et al. Plasma lipids in premenopausal women with mammographic dysplasia. Br J Cancer 1989 May;59:766-71.
20. Mady EA. Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. J Steroid Biochem Mol Biol 2000 Dec 31;75:323-8.
21. Manjer J, Kaaks R, Riboli E, Berglund G. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the malmo preventive project. Eur J Cancer Prev 2001 Feb;10:33-42.
22. Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem 2001 Feb;34:71-6.
23. Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control 1994 Nov;5:501-9.
24. Schreier LE, Berg GA, Basilio FM, et al. Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int 1999 Apr;47:681-90.
25. Moorman PG, Hulka BS, Hiatt RA, et al. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev 1998 Jun;7:483-8.
26. Byrne C, Colditz GA, Willett WC, et al. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000 Jul 15;60:3744-8.
27. Guo YP, Martin LJ, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001 Mar;10:243-8.
28. Maskarinec G, Williams AE, Kaaks R. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 2003 Dec 20;107:991-6.
29. McTiernan A, Ulrich CM, Yancey D, et al. The physical activity for total health (PATH) study: rationale and design. Med Sci Sports Exerc 1999 Sep;31:1307-12.
30. Irwin ML, Yasui Y, Ulrich CM, et al. Effect of exercise on total and intraabdominal body fat in postmenopausal women: a randomized controlled trial. JAMA 2003 Jan 15;289:323-30.
31. Tworoger SS, Yasui Y, Ulrich CM, et al. Mailing strategies and recruitment into an intervention trial of the exercise effect on breast cancer biomarkers. Cancer Epidemiol Biomarkers Prev 2002 Jan;11:73-7.
32. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian national breast screening study. J Natl Cancer Inst 1995;87:670-5.
33. Tworoger SS, Yasui Y, Chang L, Stanczyk FZ, McTiernan A. Specimen allocation in longitudinal biomarker studies: controlling subject-specific effects by design. Cancer Epidemiol Biomarkers Prev 2004 Jul;13:1257-60.
34. McTiernan A, Tworoger SS, Ulrich CM, et al. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res 2004 Apr 15;64:2923-8.
35. Goebelsmann U, Bernstein GS, Gale JA, et al. Vasectomy: immunologic and pathophysiologic effects in animals and man. Lepow LH, Crozier R, editors. Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. New York: Academic Press; 1979. p. 165.
36. Probst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6:165-73.
37. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999 Oct;84:3666-72.
38. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982 Jun;16:801-10.
39. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol 1986;129:101-23.
40. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982 Jun;28:1379-88.
41. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 Jun;18:499-502.
42. Ursin G, Palla SL, Reboussin BA, et al. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the postmenopausal estrogen/ progestin interventions (PEPI) trial. J Clin Oncol 2004 Jul 15;22:2842-8.
43. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 1995 Jan;85:6-10.
44. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993 Feb-Mar 31;57:237-57.
45. Armamento-Villareal RC, Napoli N, Klug T, Civitelli R. The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women. Bone 2004 Sep;35:682-8.
46. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 1997 Oct 11;350:1047-59.
47. Sendag F, Cosan Terek M, Ozsener S, et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001;76:445-50.
48. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-52.
49. Boyd NF, Connelly P, Byng J, et al. Plasma lipids, lipoproteins, and mammographic densities. Cancer Epidemiol Biomarkers Prev 1995 Oct-Nov 30;4:727-33.
50. Byng JW, Yaffe MJ, Lockwood GA, et al. Automated analysis of mammographic densities and breast carcinoma risk. Cancer 1997 Jul 1; 80:66-74.